Relaxin, the mammalian 6-kDa heterodimeric polypeptide hormone, is a member of the insulin-like superfamily ([@b37]) and consists of seven peptides of high structural but low sequence similarity. Relaxin plays an essential role in the biological processes such as metabolism, growth, pregnancy, and parturition in different species including humans and rodents. Relaxin circulates in these species during pregnancy emanating from the corpus luteum (Conrad & [@b11]) and placenta ([@b31]); however, temporal pattern of change and serum concentrations of this hormone are different. In rodents, circulating relaxin peak concentrations at the end of pregnancy reach 100 ng/mL, two times greater than in human ([@b72]). While relaxin plays important role in collagen catabolism of the pubic symphysis during gestation in lower mammals such as mice and rats ([@b64]), the role of this hormone on pubic symphysis of human is however unknown ([@b35]; [@b91]). Several studies have highlighted the therapeutic potential of relaxin for ectopic pregnancy, male infertility, and heart failure, cardiovascular and musculoskeletal diseases. Currently, there are seven known relaxin family peptides (RXFP) that are structurally related to insulin which include relaxin (RLN)1, RLN2, RLN3, and insulin-like peptide (INSL)3, INSL4, INSL5, and INSL6 ([@b4]). RLN1 and RLN2 are strong regulators of collagen expression and metabolism in fibroblasts, and are differentially expressed in the corpus luteum, decidua, and endometrium, as well as prostate tissue, while RLN3 is specific to the brain ([@b71]). Relaxin1 and 2 reconcile the hemodynamic changes occurring during pregnancy such as cardiac output, renal blood flow, and arterial compliance ([@b10]), as well as weakening the pelvic ligaments for parturition in species such as guinea pigs and mice ([@b73]). RLN3 is a highly conserved neuropeptide in vertebrates, and is involved in a wide range of neuroactivities such as response to stress and cognition, as well as in neurological disease ([@b80]).

Relaxin binds to RXFP receptors and exerts its action through a ligand-receptor system in multiple pathways. The relaxin receptor is involved in signal transduction between extracellular/intracellular domains. Relaxin1--4 hormones are ligands for the RXFP1, RXFP2, RXFP3, and RXFP4, respectively (Fig. [1](#fig01){ref-type="fig"}). This family peptides act on four G-protein-coupled receptors (GPCRs; formerly LGR7, LGR8, GPCR135, and GPCR142) ([@b40]). RXFP1 and RXFP2 are composed of large extracellular domains which encompass of leucine-rich repeats. On the other hand, RXFP3 and RXFP4 proteins are more similar to small peptide ligands ([@b83]). Recently, it has been shown that there is a difference in the ligand binding mode between RXFP1 and RXFP2 ([@b70]). RXFP1 and RXFP2 exist in uterus, cervix, vagina, brain, and heart of a number of animal species. However, production of these proteins differs among tissues of various species. For example, RXFP1 is expressed in rats and mice myometrium ([@b88]), whereas in human, this receptor is mainly localized to the endometrium ([@b8]). Moreover, RXFP1 is expressed in the rats and mice heart localized to the atria where it mediates positive inotropic and chronotropic responses ([@b61]), while there is currently no report of this receptor binding or function in the human heart.

![Interaction of RLN1, RLN2, and RLN3 proteins with their receptors RXFP1, RXFP2, and RXFP3, respectively, as well as with insulin-like growth factor (INSL3) and rearranged L-myc fusion (RFL) in the network (<http://www.genecards.org/>).](sms0024-e220-f1){#fig01}

Evidence also suggests that the functional domains of RXFP1, the cell type in which it is expressed, and the ligand used to activate the receptor all have important roles in the musculoskeletal system (Fig. [2](#fig02){ref-type="fig"}). Relaxin alters cartilage and tendon stiffness by activating collagenase ([@b35]; [@b57]). Relaxin is also involved in bone remodeling process and in healing of injured ligaments and skeletal muscles ([@b44]; [@b17]). The soft tissue healing cascade is composed of three phases, inflammation, regeneration, and fibrosis, and relaxin is a regulator of both inflammation and fibrosis ([@b52]). Relaxin also acts as antifibrotic agent, and favors muscle regeneration and against muscle fibrosis to promote regrowth of myofibers in skeletal muscle healing. In this review, our aim is to summarize and critically investigate the available data, strictly related to relaxin and its regulatory effect on the musculoskeletal system.

![A summary of relaxin role in the locomotor system.](sms0024-e220-f2){#fig02}

Relaxin function in the musculoskeletal system
==============================================

The musculoskeletal system is composed of bone, synovium, ligament, muscle, tendon, articular cartilage, and the related connective tissues that support the body\'s ability to move ([@b20]). Relaxin plays an integral role in the remodeling of multiple tissues of the musculoskeletal system.

Bone
====

Relaxin along with hormones such as estrogen and growth factors such as transforming growth factor-beta (TGF-β) helps orchestrate the bone remodeling process. These factors regulate a cytokine system containing three fundamental molecules: the receptor activator of nuclear factor κB ligand (RANKL), RANK, and osteoprotegerin (OPG). In the RANKL/RANK/OPG system, RANKL on the preosteoblastic/stromal cells binds to its receptor (RANK) on the osteoclastic precursor cells and induces expression of a variety of genes to provide the crucial signal to drive osteoclast recruitment and development ([@b19]). OPG regulates the system through blocking the effects of RANKL and interfering with RANK signaling. Relaxin facilitates differentiation of peripheral blood mononuclear cells into mature osteoclasts during osteoclastogenesis by stimulating osteoblastic/stromal cell production, while estrogen inhibits this process through increasing OPG production ([@b19]). Therefore, relaxin is one of the osteoclast-activating factors that increase bone resorption. It is also overexpressed in tumors that promote growth, differentiation, and invasiveness, which lead to osteolytic metastases (Clezardin & [@b9]). Together, these data indicate a possible role of relaxin in osteoclastogenesis ([@b19]; [@b22]). Relaxin 2 (RLX2) regulates bone metabolism and proliferation in human osteoblasts. Stimulation of osteoblasts with RLX2 activates adenylate cyclase (AC) and increases cAMP production by G- proteins and thereby increases cell proliferation ([@b23]). Previous studies have identified an inactivating mutation in the RXFP2 gene (T222P), which caused idiopathic osteoporosis in young men through functional osteoblast impairment and reduced bone density ([@b23]). A similar result was also observed in knockout mouse model ([@b24], [@b25]). There is also some evidence to suggest that higher levels of estrogen and relaxin in pregnant women correlated with an increased prevalence of congenital dysplasia of the hip in neonates (Uden & [@b86]; [@b68]; [@b82]). In view that relaxin affects both osteoclast and osteoblast, therefore this hormone is involved in bone remodeling process, and stimulation of osteoblast by RLX2 suggests that this hormone is potentially useful in the treatment of bone condition such as osteoporosis.

Synovium
========

Relaxin in combination with estrogens may also have therapeutic value in the treatment of rheumatoid arthritis (RA) ([@b65]; [@b38]). RA is a chronic and systemic inflammatory disorder that may affect many tissues and organs, but also causes bone destruction through synovial hypertrophy. However, the incidence and severity of this disease during pregnancy is lower than normal. During pregnancy, relaxin and estrogen levels in the serum are elevated leading to decrease in inflammation in RA patients ([@b13]; [@b38]). Relaxin exerts its anti-inflammatory effect through down-regulation of neutrophil function ([@b2]) and stimulates leukocyte adhesion and migration in human mononuclear cells ([@b26]). A combined treatment using relaxin and estrogen appears to reduce circulating tumor necrosis factor-α level in rat adjuvant-induced arthritis model of RA and increased the anti-inflammatory cytokine IL-10 in human cells. ([@b65]; [@b26]). In view of this, relaxin has a potential beneficial effect in the treatment of synovial diseases.

Ligament
========

Relaxin hormone alters ligament mechanics due to its collagenolytic effect mediated by discharge of matrix metalloproteinases (MMPs) ([@b63]), collagenase ([@b93]; [@b32]), and plasminogen activator ([@b39]). Relaxin treatment in pregnant cattle increased pelvic width and height (Perezgrovas & [@b58]; [@b53]), but not in other joints such as wrist and knee ([@b92]; [@b47]). Increase in serum relaxin concentration may also correlate with joint laxity ([@b45]; [@b15], [@b16]), but this effect during pregnancy is controversial ([@b28]). Some studies have reported higher relaxin levels in pregnant women with pelvic joint instability or hip joint laxity as compared with controls ([@b68]; [@b82]), while other studies did not ([@b56]). Two studies on the relationship between serum relaxin levels and joint laxity reported no significant association between this hormone level and knee and generalized joint laxity ([@b1]; [@b95]). Studies have also suggested a relationship between higher relaxin and progesterone serum levels in pregnant females with pelvic girdle pain syndrome ([@b46]; [@b97]; [@b41]) and pelvic floor dysfunction ([@b34]), whereas other studies have not found such a relationship (Crelin & [@b12]; [@b60]; [@b90]). Study design and methodological differences may account for some of the conflicting data.

Relaxin appears to play a role in anterior cruciate ligament (ACL) injury ([@b21]; [@b17]). Estrogen and relaxin receptors have been found in the human female ACL ([@b21]). Studies on the mechanical properties of human ACLs illustrate that those treated with relaxin have reduced ligament integrity and may be at higher risk of injury (Toth & [@b85]; [@b15]). This finding was also replicated in an animal model, where rabbits treated with relaxin had significantly weaker ACLs compared with controls. Additionally, there was increased anterior tibial displacement on radiographic assessment, indicating ACL laxity, in animals treated with relaxin ([@b17]).

There may also be an association between ACL injuries and stages of menstrual cycle. Occurrence of ACL injuries during the ovulatory phase (midcycle) is more frequent than the luteal phase ([@b94]). During this period, estrogen and relaxin levels are high; therefore, activation of the estrogen and relaxin receptors may be increased (Min & [@b51]; [@b79]). Relaxin activates collagenolytic system which increases collagenase synthesis and finally degrades the extracellular matrix composition ([@b30]; [@b33]).

A prospective study of elite female athletes illustrated that players with increased serum relaxin levels had an increased risk of an ACL tear compared with females with lower relaxin levels ([@b15]). Players having a relaxin concentration of greater than 6.0 pg/mL had more than four times greater risk of ACL injury. Other studies have collaborated these findings ([@b69]; [@b94]; [@b5]; [@b15]). Relaxin appears to affect other ligaments such as volar oblique in perimenopausal women via a receptor-mediated process. In this ligament, relaxin particularly binds and probably reveals in presence of cellular or extracellular matrix receptors ([@b45]). Taken together, these findings indicate that while relaxin effects are beneficial to the lower animals especially during pregnancy, its proposed effect on the peripheral ligament laxity in humans and animals may predispose the joint to a non-traumatic injury.

Muscle
======

Relaxin helps regulate normal skeletal muscle through two principle signaling pathways: AC and nitric oxide (NO). Relaxin activates the AC signaling pathway in skeletal muscles through the following signal chain: relaxin receptor tyrosine kinase → Gi protein (βγ-dimer) → phosphatidylinositol 3-kinase (PI3K) → protein kinase Cz (PKCζ) → heterotrimeric Gs protein → AC → protein kinase A ([@b43]; [@b77], [@b74], [@b75], [@b76], [@b78]; [@b59]; [@b62]). Relaxin also activates the NO pathway in skeletal muscle via relaxin-mediated activation of receptor tyrosine kinase → Gi protein → PI3K → protein kinase D1 → protein kinase B → NO ([@b62]). NO regulates various biological processes, and is produced by NO synthase (Stamler & [@b81]). There are data that indicate relaxin stimulates NO synthase signaling in the skeletal muscles of type 2 diabetic rats, leading to NO dysfunction ([@b42]).

Relaxin may be implicated in the skeletal muscle healing process by regulating inflammation, tissue remodeling, and fibrosis ([@b27]; [@b71]). The degree of fibrotic response varies with the level of inflammation and injury. Relaxin may improve spontaneous regeneration of injured skeletal muscle as illustrated in an injured muscle mouse model ([@b29]; [@b67]). During this process, skeletal muscle cells regenerate and repair to reduce the size of a damaged or necrotic area and replace it with new living tissue. Degeneration/inflammation is a retrogressive change in cells and tissues characterized by abnormal structural changes and decreased functions ([@b44]; [@b50]; [@b55]; [@b52]). Relaxin has been reported to regulate several steps during inflammation which include inhibition of platelet aggregation ([@b3]), inhibits activation and recruitment of neutrophils to the site of inflammation ([@b18]), and promotes migration of mononuclear leucocytes through RXFP1-dependent mechanism ([@b26]).

In regeneration phase, immature granulation tissue containing active fibroblasts produces abundant type III collagen, which fills the defect left by an open wound ([@b89]). Granulation tissue moves, as a wave, from the border of the injury toward the center. As granulation tissue matures, fibroblasts produce less collagen and become more spindly in appearance, which then begin to produce a much stronger type I collagen ([@b84]). Some of the fibroblasts mature into myofibroblasts containing similar actin to the smooth muscle, which enables them to contract and reduce the size of the wound ([@b66]). Fibrosis is the last phase of healing where a non-functional scar tissue is formed caused by excessive accumulation of connective tissue following damage. Fibrosis often delays and impairs the recovery of damaged tissue (Diegelmann & [@b14]). Relaxin has been shown to inhibit fibrosis formation through several mechanisms that include neutralization of the effect of TGFβ1 and activation of the collagenolytic system, which increases collagenase synthesis ([@b30]; [@b33]; [@b48], [@b49]; [@b52]; [@b87]). Through these mechanisms, relaxin reduces the formation of fibrous scar tissue (Fig. [3](#fig03){ref-type="fig"}). Relaxin administration to the injured skeletal muscle promotes activation of satellite cells, induces angiogenesis and revascularization, as well as represses the extended inflammatory reaction ([@b52]). Recently, relaxin administration to diabetic wound in mice has been shown to up-regulate the mRNA expression of vascular endothelial growth factor, epithelial NO, and stromal-cell-derived factor 1-α, stimulates angiogenesis and vasculogenesis, enhances MMP-11 expression, and increases wound-breaking strength ([@b6]). In view that relaxin plays important role in the healing process, it can potentially be used as a therapeutic agent to treat damaged skeletal muscle ([@b55]).

![A competition exists between fibrosis and regeneration during healing of damage tissue. Relaxin and transforming growth factor-beta1 (TGF-β1) make imbalance between regeneration and fibrosis process. Increased relaxin and decreased TGF- β1 result in regeneration and consequently healing, while decreased relaxin and increased TGF- β1 lead to fibrosis.](sms0024-e220-f3){#fig03}

Tendon
======

Relaxin has been reported to effect tendon metabolism by controlling the length of tendon growth ([@b46]; [@b96]) and reduce tendon stiffness by increasing tendon laxity through activation of collagenase ([@b57]). An *in vivo* study investigating the growth of rat tails and human patellar tendons showed that relaxin levels correlate with tendon length ([@b96]; [@b57]). Rat tail tendons treated with relaxin exhibited alterations in collagen through interfering with fibril association and collagen sliding ([@b96]). Another study in women with normal menstrual cycle, who did not take any contraception pills, demonstrated a significant link between serum relaxin levels and patellar tendon stiffness ([@b57]). Besides the reported effects of relaxin on the tendon, potential benefits of relaxin on tendon repair and remodeling are largely unknown.

Cartilage
=========

Relaxin appears to decrease knee articular cartilage stiffness ([@b7]; Hellio Le [@b36]) through induction of collagenase-1, MMP-1, and MMP-3, which reduces collagen content and expression in fibrocartilaginous cells. Modulation of MMPs to loss of collagen by hormones may contribute selectively to degeneration of specific joints fibrocartilaginous explants facilitated by proteinases ([@b54]; [@b35]). The degradation of extracellular matrix in fibrocartilage is synergized by β-estradiol. Relaxin exerts its effect through binding to RXFP1 and RXFP2 receptors (Hellio Le [@b36]; [@b91]). The ratio of RXFP2 in knee meniscus of pregnant rabbits was shown to be more than RXFP1, which may indicate differential role of these receptors in the remodeling of fibrocartilage (Hellio Le [@b36]; [@b91]). Comparison of collagen content in articular cartilage of nonpregnant and pregnant rabbits showed that the total RNA levels and chondrocyte metabolism decreased during pregnancy. Depending on the level of skeletal maturity, pregnancy can exert both general and specific effects on the RNA levels in articular cartilage of the rabbit knee (Hellio Le [@b36]). Thus, relaxin may play a role in women\'s susceptibility to musculoskeletal disease ([@b54]). Taken together, these findings suggested that in female, increased relaxin level may result in undesirable effects on the articular cartilage.

Perspective
===========

Relaxin plays a vital role in biological processes including metabolism, growth, and reproduction. Among the four relaxin types, RLN1 and RLN2 regulate the musculoskeletal system via multiple pathways through a ligand-receptor system, depending on cell type and ligand (Table [1](#tbl1){ref-type="table"}). Our investigation of relaxin\'s role in the musculoskeletal system showed some limitations in the literature. For example, most of the reports did not delineate the relaxin isoform or its specific receptor. Additionally, despite relaxin\'s accepted role in the regulation of AC and NO pathways, few studies have focused on the regulatory effect of these pathways in the musculoskeletal organs. Although relaxin may affect many ligaments and tendons of the musculoskeletal system, previous studies have mostly concentrated on the anterior cruciate and wrist ligaments. Future studies are warranted to gain a better understanding of relaxin\'s role in the musculoskeletal system.

###### 

Review of previously reported data of relaxin in the locomotor system

  Organ       Author (year)                                          Sample                               Model                                      Treatment                            Relaxin                                                                         Role of relaxin
  ----------- ------------------------------------------------------ ------------------------------------ ------------------------------------------ ------------------------------------ ------------------------------------------------------------------------------- ---------------------------------------------------------------
  Skeleton                                                                                                                                                                                                                                                                
  Cartilage   [@b7]                                                  Chondrocyte cell                     Rb/vitro                                   Porcine relaxin                      NI                                                                              Modulation of type I, II, III collagen expression
  [@b54]      Joint fibrocartilaginous cells                         Rb/vitro                             Human relaxin, β-estradiol                 NI                                   No increase collagenase1 and MMP3 expression                                    
  [@b35]      Knee meniscus fibrocartilage and articular cartilage   Rb/vitro                             Human relaxin, β-estradiol, progesterone   NI                                   No significant change of GAGs and collagen                                      
  [@b91]      Joint fibrocartilaginous cells                         M/vitro                              NI                                         1,2                                  Expression of RXFP2 \> RXFP1                                                    
  Bone        [@b65]                                                 Arthritis paw                        R/vivo                                     Porcine relaxin and 17-β-estradiol   NI                                                                              Combination hormone therapy reduced arthritis inflammation
  [@b1006]    Normal osteoblast cell                                 H/vitro.                             Relaxin                                    1,2                                  Bone resorption by mediators                                                    
  [@b24]      Bone densitometry, cryptorchidism, osteoblast cell     H,M/vivo, vitro                      Agonists INSL3, relaxin, forskolin         2                                    Links RXFP2 gene mutations with human osteoporosis                              
  [@b19]      Osteoclast cell                                        H/vitro                              Relaxin                                    1                                    Facilitation of the differentiation of osteoclasts                              
  [@b23]      Osteoclast cell                                        H/vitro                              Relaxin                                    1                                    Relaxin is a potent stimulator of osteoclastogenesis                            
  [@b25]      Femoral heads osteoblast cell                          H/vitro                              Relaxin 2                                  2                                    RXFP2 system is involved in bone metabolism                                     
  [@b38]      Joint tissues, murine osteoblast cells                 R/vivo and vitro                     17-β-estradiol, porcine relaxin            NI                                   Modulation of RANKL-OPG system                                                  
  Joint       [@b92]                                                 Four nonpregnant and 11 pregnant     H/vivo                                     Relaxin as releasin                  NI                                                                              No change in pelvic measurement
  [@b12]      Pelvic joints                                          R/vivo                               Relaxin, estrogen                          NI                                   No difference in pelvic joint flexibility                                       
  [@b58]      Pelvic joint                                           BF/vivo                              Porcine relaxin                            NI                                   Expansion of the pelvic area (p)                                                
  [@b46]      Patients with late pregnancy                           H/vivo                               NI                                         NI                                   High relaxin link between pelvic pain and joint laxity during late pregnancy    
  [@b53]      Pelvic joint                                           BF/vivo                              Relaxin                                    NI                                   Induction of pelvic expansion, highly significant interaction (p)               
  [@b86]      CDH patients                                           H/vivo                               NI                                         NI                                   Increased sensitivity of the receptors of the fibroblasts                       
  [@b68]      153 pregnant women                                     H/vivo                               NI                                         NI                                   Congenital hip dysplasia rate, consistent with estrogen and relaxin levels      
  [@b60]      472 pregnant women                                     H/vivo                               NI                                         NI                                   Not associated with pregnancy pelvic pain                                       
  [@b97]      19 women                                               H/vivo                               Oral contraceptive                         NI                                   Higher relaxin with posterior pelvic and lumbar pain                            
  [@b69]      21 women                                               H/vivo                               NI                                         2                                    No correlation with serum relaxin and joint laxity                              
  [@b28]      90 newborn children                                    H/vivo                               NI                                         NI                                   NI lower relaxin in newborns with pelvic presentation hip instability           
  [@b1007]    12 girls, three boys newborn                           H/vivo                               NI                                         2                                    Reduction of relaxin concentration with increasing sonographic hip              
  [@b41]      200 pregnant women                                     H/vivo                               NI                                         NI                                   Relaxin correlated with pelvic pain in early pregnancy                          
  [@b56]      Knee joint of nonpregnant and pregnant                 R/vivo                               NI                                         NI                                   Relaxin preventing the development of joint contracture                         
  [@b1]       Athlete eumenorrheic women and men                     H/vivo                               NI                                         NI                                   No effect on knee laxity                                                        
  [@b47]      Pregnant women                                         H/vivo                               NI                                         NI                                   No correlation of wrist joint laxity and relaxin level                          
  [@b34]      Pregnant women                                         H/vivo                               NI                                         NI                                   Higher relaxin and fall significantly faster in women with PFD                  
  [@b90]      212 women pelvic joints                                H/vivo                               NI                                         NI                                   Contribution with pelvic joint laxity but no responses to pain and disability   
  [@b95]      289 healthy human                                      H/vivo                               NI                                         2                                    No link between serum relaxin and generalized joint laxity                      
  Ligament    [@b1002]                                               455 pregnant women                   H/vivo                                     NI                                   NI                                                                              No difference in serum relaxin concentration with pelvic pain
  [@b1004]    ACL specimens                                          H/vitro                              Human recombinant relaxin                                                       Binding of relaxin female ACL tissues but not in men ACL                        
  [@b1005]    ACL specimens                                          H/vitro                              Human relaxin                              NI                                   Competence of the ACL to sequester relaxin                                      
  [@b21]      ACL injuries cells                                     H/vitro                              NI                                         NI                                   Increased binding of relaxin labeled in ACL fibroblast cells more in female     
  [@b45]      VOL                                                    H/vitro                              NI                                         NI                                   Relaxin binds to VOL perimenopausal women                                       
  [@b17]      ACL specimens                                          G/vivo                               Porcine relaxin/estrogen                   NI                                   Alternation of mechanical properties of the ACL                                 
  [@b16]      Female athletes                                        H/vivo                               NI                                         2                                    Higher relaxin in ACL tears than without tears                                  
  Muscular                                                                                                                                                                                                                                                                
  Muscle      [@b43]                                                 Type 1,2 diabetes skeletal muscles   R/vitro                                    Insulin/relaxin/IGF-1                NI                                                                              No regulation activity of glycogen synthase by relaxin
  [@b77]      Skeletal muscles                                       R/vitro                              Inhibitor                                  NI                                   Inhibitor blocked stimulatory effect of relaxin on adenylate cyclase            
  [@b44]      Tibialis anterior muscles                              M/vivo                               Relaxin                                    NI                                   Regeneration and prevention of fibrosis                                         
  [@b50]      Internal obturator muscles with PH                     D/vivo                               NI                                         1                                    Pathogenesis role of relaxin on PH                                              
  [@b55]      Skeletal muscles, myoblasts (C2C12 cells)              R/vivo and vitro                     Relaxin                                    NI                                   Antifibrosis agent and improves the healing                                     
  [@b74]      Skeletal muscles                                       R/vivo                               Pig relaxin 2                              1,2                                  Relaxin2 stimulated the AC activity                                             
  [@b78]      Myoblastic cell line                                   R/vitro                              Relaxin                                    1                                    Stimulation of adenylyl cyclase activity                                        
  [@b76]      Skeletal muscles                                       R/vivo                               Porcine relaxin 2                          2                                    Regulation of adenylyl cyclase system under hyperglycemia                       
  [@b1001]    Skeletal muscles                                       F/vitro                              Relaxin                                    2                                    Relaxin in increasing G-6-PDH activity                                          
  [@b42]      Type 2 diabetes skeletal muscles                       R/vitro                              Streptozotocin                             NI                                   Stimulation of NO synthase in rat skeletal muscles                              
  [@b52]      C2C12 mouse/myoblast cell, muscle                      H, M/vivo, vitro                     Relaxin                                    1                                    Regeneration/increased angiogenesis/revascularization                           
  Tendon      [@b96]                                                 Tail tendon                          R/vivo                                     Pentapeptide NKISK, relaxin          NI                                                                              Significantly more creep and changes in tendon length
  [@b57]      Patellar and medial gastrocnemius tendon               H/vivo                               NI                                         NI                                   Correlations between relaxin and patellar tendons stiffness                     

Rb, rabbit; M, mouse; H, human; D, dog; R, rat; F, fish; BF, beef heifer; G, guinea pig; AC, adenylate cyclase; ACL, anterior cruciate ligament; CDH, congenital dysplasia of the hip; GAG, glycosaminoglycan; NI, no identification; NO, nitric oxide; OPG, osteoprotegerin; PDH, phosphate dehydrogenase; PFD, pelvic floor dysfunction; PH, Perineal Hernia; RANKL, receptor activator of nuclear factor κB ligand; VOL, volar oblique ligament.
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